NCT00407355View on ClinicalTrials.gov

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

Intravitreal injection of ranibizumab .3 dose

PRN every 30 days withing retreatment criteria

DRUG

Intravitreal injection of Ranibizumab .5 dose

Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria

Trial Locations (1)

21287

Wilmer Eye Institute, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Peter A Campochiaro, MD

OTHER